Skip to content

On Minimizing Risk and Harm in the Use of Psychedelics.

Jules Evans, Marc Aixalà, Brian T Anderson, William Brennan, Rebecka Bremler, Joost J. Breeksema, Lisa Burback, Abigail E. Calder, Robin Carhart-Harris, Katherine Cheung, Neşe Devenot, Ingmar Gorman, Jakub Greń, Peter S. Hendricks, Brian Holoyda, Edward Jacobs, Joy Krecké, Daniel J. Kruger, David Luke, Tomislav Majić, Amy L. Mcguire, Nicky J. Mehtani, David S. Mathai, Kristin Nash, Tehseen Noorani, Roman Palitsky, Oliver Robinson, Otto Simonsson, Elin Stahre, Michiel van Elk, David B. Yaden

Psychiatric Research and Clinical Practice February 11, 2025 DOI: 10.1176/appi.prcp.20240128 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Survey Peer reviewed
Sample size 30
Population Psychedelic researchers
Topics Psychedelic-assisted therapy
Keywords Mental health safety Therapeutic protocols Harm reduction Clinical guidelines
Citations 18
Key findings Critical research gaps include defining types of psychedelic harm, predicting those harms, and treating them effectively, along with a call for better support and funding for a psychedelic safety net.

Abstract

Objective: This article outlines recommendations from 30 psychedelic researchers on how to create a better psychedelic safety net.

Methods: A survey of 30 psychedelic researchers asked them to identify key critical research gaps around psychedelic harm and safety.

Results: The critical research gaps identified by the authors included defining the main types of psychedelic harm, the predictors of those harms, and the most effective way to treat those harms. They also call for better support for those experiencing post-psychedelic difficulties, including better online information, peer support groups, affordable therapy, and psychiatric consultation and medication. Finally, the authors call for better funding to create a psychedelic safety net, and suggest psychedelic philanthropists, investors and companies could commit 1% of their investment in psychedelics into supporting safety measures such as research and support services.

Conclusions: The authors identify several practical steps to create a better psychedelic safety net and call for more funding to psychedelic safety measures such as research and support services. Relevance to clinical practice: The authors outline important gaps in our knowledge around the safety and risk profile of psychedelic medicines and identify practical steps forward for researchers and clinical practitioners to make this promising field safer.

Comparable studies

Other cross-sectional and survey studies on psychedelic-assisted therapy, most cited first.

Study Year Design Participants
Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. International sample of people who reported having used a psychedelic 2020 Cross-sectional survey n = 985
Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment Among US Special Operations Forces Veterans U.S. Special Operations Forces Veterans who completed a psychedelic clinical program in... 2020 Survey n = 51
Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics Respondents from the National Survey on Drug Use and Health, 2008–2017, weighted to... 2020 Cross-sectional survey n = 260,964,827
Examination of the Phenomenology of the Ibogaine Treatment Experience: Role of Altered States of Consciousness and Psychedelic Experiences. Individuals who used ibogaine in the past 2017 Retrospective survey n = 27
American Psychiatrists' Opinions About Classic Hallucinogens and Their Potential Therapeutic Applications: A 7-Year Follow-Up Survey. American Psychiatric Association members (resident-fellows and attending psychiatrists) 2024 Survey n = 131

Citations in the library

Explore topics